Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age

Pediatric Infectious Disease Journal

Volumn 33, Issue 12, 2014, Pages 1262-1269

  Weber, Miguel A Rodriguez ^a   Claeys, Carine ^b   Doniz, Carlos Aranza ^c,e   Feng, Yang ^b   Innis, Bruce L ^d   Jain, Varsha K ^d   Peeters, Mathieu ^b  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b GSK   (Belgium)

^c Centro Medico Adolfo Lopez Mateos   (Mexico)

^d GLAXOSMITHKLINE   (United States)

^e Comision Nacional De Proteccion Social En Salud ^*  (Mexico)

Author keywords

Children; Quadrivalent; Seasonal influenza; Trivalent; Vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; TRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BRONCHOPNEUMONIA; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SAFETY; SIDE EFFECT; URTICARIA; VACCINATION; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFANT; INFLUENZA, HUMAN; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROCEDURES;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, INACTIVATED;

EID: 84926022987     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000463     Document Type: Article

References (27)

1. Bhat N, Wright JG, Broder KR, et al; Influenza Special Investigations Team. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567.
2. Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
3. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369-1373.
4. Moore DL, Vaudry W, Scheifele DW, et al. Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004. Pediatrics. 2006;118:e610-e619.
5. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113(3 Pt 1):585-593.
6. Hite LK, Glezen WP, Demmler GJ, et al. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis. 2007;11:40-47.
7. Hu JJ, Kao CL, Lee PI, et al. Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect. 2004;37:95-98.
8. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003;36:299-305.
9. Centers for Disease Control and Prevention. Influenza-associated pediatric deaths-United States, September 2010-August 2011. Morb Mortal Wkly Rep. 2011;60.
10. Verani JR, McCracken J, Arvelo W, et al. Surveillance for hospitalized acute respiratory infection in Guatemala. PLoS One. 2013;8:e83600.
11. Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59-68.
12. United States Centers for Disease Control and Prevention. Seasonal influenza activity surveillance reports: 2000-2001 to 2010-2011 seasons. Available at: http://www.cdc.gov/flu/weekly/pastreports.htm.
13. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-88.
14. Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28:2149-2156.
15. Belongia EA, Kieke BA, Donahue JG, et al.; Marshfield Influenza Study Group. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199:159-167.
16. Tricco A, Chit A, Soobiah S, Hallett D, Meier G, Chen M, Tashkandi M, Bauch C, Loeb M. Effect of influenza vaccination against mismatched strains: a systematic review. Canadian Immunization Conference. Vancouver, Canada; Dec. 3-5, 2012 [Abstract].
17. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. 2012; http://www.who.int/influenza/vaccines/virus/recommendations/201202-recommendation. pdf. Accessed February 11, 2014.
18. Centers for Disease Control and Prevention. Interim Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. Available at: http://www.cdc.gov/flu/professionals/acip/2013-interim-recommendations. htm. Accessed February 11, 2014.
19. Hehme N, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix". Clin Drug Invest. 2002;22:751-769.
20. Food and Drug Administration. Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. May 2007. Available at: http://www.fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed February 11, 2014.
21. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2009;58 (RR-8).
22. Advisory Committee on Immunization Practices. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-13 Influenza Season. Morb Mortal Wkly Rep. August 17, 2012;61:613-618.
23. Gilca V, De Serres G, Hamelin ME, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine. 2011;30:35-41.
24. Skowronski DM, Hottes TS, De Serres G, et al. Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J. 2011;30:833-839.
25. Skowronski DM, Hamelin ME, Janjua NZ, et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One. 2012;7:e38929.
26. Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208:544-553.
27. Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013;9:1978-1988.